Patents Assigned to Theraclone Sciences, Inc.
  • Patent number: 10865234
    Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: December 15, 2020
    Assignees: THERACLONE SCIENCES, INC., INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Po-Ying Chan-Hui, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos, Stephen Kaminsky
  • Patent number: 10836811
    Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: November 17, 2020
    Assignees: Theraclone Sciences, Inc., The Scripps Research Institute, International AIDS Vaccine Initiative
    Inventors: Po-Ying Chan-Hui, Katherine Doores, Michael Huber, Stephen Kaminsky, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Majorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos
  • Patent number: 10407493
    Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: September 10, 2019
    Assignees: THERACLONE SCIENCES, INC., INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Po-Ying Chan-Hui, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos, Stephen Kaminsky
  • Patent number: 10239934
    Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: March 26, 2019
    Assignees: Theraclone Sciences, Inc., International AIDS Vaccine Initiative, The Scripps Research Institute
    Inventors: Po-Ying Chan-Hui, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos, Stephen Kaminsky
  • Patent number: 10087239
    Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: October 2, 2018
    Assignees: THERACLONE SCIENCES, INC., THE SCRIPPS RESEARCH INSTITUTE, INTERNATIONAL AIDS VACCINE INITIATIVE
    Inventors: Po-Ying Chan-Hui, Katherine Doores, Michael Huber, Stephen Kaminsky, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Majorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos
  • Patent number: 9920111
    Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: March 20, 2018
    Assignees: Theraclone Sciences, Inc., International Aids Vaccine Initiative, The Scripps Research Institute
    Inventors: Po-Ying Chan-Hui, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos, Stephen Kaminsky
  • Patent number: 9464131
    Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: October 11, 2016
    Assignees: Theraclone Sciences, Inc., The Scripps Research Institute, International AIDS Vaccine Initiative
    Inventors: Po-Ying Chan-Hui, Katherine Doores, Michael Huber, Stephen Kaminsky, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos
  • Patent number: 9051362
    Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: June 9, 2015
    Assignees: Theraclone Sciences, Inc., International AIDS Vaccine Initiative, The Scripps Research Institute
    Inventors: Po-Ying Chan-Hui, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos
  • Patent number: 8974788
    Abstract: The present invention provides compositions, vaccines, and methods for diagnosing, treating, and preventing influenza infection using a combination of antibodies raised against the influenza hemagglutinin and the matrix 2 ectodomain polypeptides.
    Type: Grant
    Filed: August 12, 2010
    Date of Patent: March 10, 2015
    Assignee: Theraclone Sciences, Inc.
    Inventors: Andres G. Grandea, III, Gordon King, Thomas C. Cox, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Phil Hammond
  • Patent number: 8932597
    Abstract: The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: January 13, 2015
    Assignee: Theraclone Sciences, Inc.
    Inventors: Matthew Moyle, Jennifer Mitcham
  • Patent number: 8916160
    Abstract: The present invention provides compositions, vaccines, and methods for diagnosing, treating, and preventing influenza infection using a combination of antibodies raised against the influenza hemagglutinin and the matrix 2 ectodomain polypeptides.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: December 23, 2014
    Assignee: Theraclone Sciences, Inc.
    Inventors: Andres G. Grandea, III, Gordon King, Thomas C. Cox, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Phil Hammond
  • Patent number: 8900590
    Abstract: The present invention provides novel human anti-Influenza antibodies and related compositions and methods. These antibodies are used in the prevention, inhibition, neutralization, diagnosis, and treatment of influenza infection.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: December 2, 2014
    Assignee: Theraclone Sciences, Inc.
    Inventors: Ole Olsen, Christina L. Boozer, Andres G. Grandea, III
  • Patent number: 8858948
    Abstract: The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: October 14, 2014
    Assignee: Theraclone Sciences, Inc.
    Inventors: Andres G. Grandea, III, Gordon King, Thomas C. Cox, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Phil Hammond
  • Patent number: 8852594
    Abstract: The present invention provides anti-cytomegalovirus antibodies and related compositions and methods. These antibodies may be used in the diagnosis, prevention, and treatment of cytomegalovirus infection.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: October 7, 2014
    Assignee: Theraclone Sciences, Inc.
    Inventor: Ole Olsen
  • Patent number: 8822651
    Abstract: The invention provides isolated fully human monoclonal anti-HRV antibodies, as well as method of making and using these antibodies. Anti-HRV antibodies of the invention prevent or treat subjects having HRV-infections, and related diseases, including, but not limited to, the common cold, nasopharyngitis, croup, pneumonia, bronchiolitis, asthma, chronic obstructive pulmonary disease (COPD), sinusitis, bacterial superinfection, and cystic fibrosis.
    Type: Grant
    Filed: August 28, 2012
    Date of Patent: September 2, 2014
    Assignee: Theraclone Sciences, Inc.
    Inventor: Po-Ying Chan-Hui
  • Publication number: 20140205612
    Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
    Type: Application
    Filed: February 28, 2013
    Publication date: July 24, 2014
    Applicants: THERACLONE SCIENCES, INC., INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Po-Ying Chan-Hui, Katherine Doores, Michael Huber, Stephen Kaminsky, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos
  • Publication number: 20140135480
    Abstract: The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.
    Type: Application
    Filed: June 10, 2013
    Publication date: May 15, 2014
    Applicant: THERACLONE SCIENCES, INC.
    Inventors: Andres G. Grandea, III, Gordon King, Thomas C. Cox, Ole Olsen, Jennifer Mitcham, Matthew Moyle
  • Patent number: 8609101
    Abstract: The invention provides a GM-CSF neutralizing human monoclonal antibody, 1783J22, as well as methods of making and use thereof. The monoclonal antibody is further characterized by its ability to bind epitopes from GM-CSF proteins of multiple species.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: December 17, 2013
    Assignee: Theraclone Sciences, Inc.
    Inventors: Po-Ying Chan-Hui, Steven Frey, Andres G. Grandea, III, Thomas C. Cox
  • Publication number: 20130158238
    Abstract: The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.
    Type: Application
    Filed: February 21, 2013
    Publication date: June 20, 2013
    Applicant: THERACLONE SCIENCES, INC.
    Inventor: THERACLONE SCIENCES, INC.
  • Patent number: 8460671
    Abstract: The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.
    Type: Grant
    Filed: August 23, 2011
    Date of Patent: June 11, 2013
    Assignee: Theraclone Sciences, Inc.
    Inventors: Andres Grandea, III, Gordon King, Thomas Cox, Ole Olsen, Jennifer Mitcham, Matthew Moyle